Stock-Based Compensation	6 Months Ended
Jun. 30, 2026
Stock-Based Compensation [Abstract]
Stock-Based Compensation	Note 5 — Stock-Based Compensation Our stockholders approved the Amended and Restated 2013 Equity Incentive Plan at our annual shareholders’ meeting in June 2026, which added a million shares to the plan; at June 30, 2026, there were 1,133,720 shares available for grant under the plan. Stock-based compensation expense included in general and administrative expense was $397 and $237, and in research and development expense was $346 and $204, for the three months ended June 30, 2026 and 2025, respectively. Stock-based compensation expense included in general and administrative expense was $789 and $427, and in research and development expense was $693 and $445, for the six months ended June 30, 2026 and 2025, respectively. 30,000 restricted stock awards were granted in both June 2026 (weighted average price of $12.72 per share) and June 2025 (weighted average price of $8.90 per share). No other awards were issued. As of June 30, 2026 and 2025, the unrecognized stock-based compensation expense related to unvested awards (including stock options, RSUs, and restricted stock) was $8,326 and $3,825, respectively, which will be amortized over an estimated weighted average period of approximately 2.91 years. During the six months ended June 30, 2026 and 2025, we cancelled 56,808 and 11,286 awards, respectively, and added them back to the plan.

Stock-Based Compensation

6 Months Ended

Jun. 30, 2026

Note 5 — Stock-Based Compensation

Our stockholders approved the Amended and Restated 2013 Equity Incentive Plan at our annual shareholders’ meeting in June 2026, which added a million shares to the plan; at June 30, 2026, there were 1,133,720 shares available for grant under the plan.

Stock-based compensation expense included in general and administrative expense was $397 and $237, and in research and development expense was $346 and $204, for the three months ended June 30, 2026 and 2025, respectively. Stock-based compensation expense included in general and administrative expense was $789 and $427, and in research and development expense was $693 and $445, for the six months ended June 30, 2026 and 2025, respectively.

30,000 restricted stock awards were granted in both June 2026 (weighted average price of $12.72 per share) and June 2025 (weighted average price of $8.90 per share). No other awards were issued.

As of June 30, 2026 and 2025, the unrecognized stock-based compensation expense related to unvested awards (including stock options, RSUs, and restricted stock) was $8,326 and $3,825, respectively, which will be amortized over an estimated weighted average period of approximately 2.91 years.

During the six months ended June 30, 2026 and 2025, we cancelled 56,808 and 11,286 awards, respectively, and added them back to the plan.